Metabolic syndrome is not a single disease but a dangerous cluster: abdominal obesity, elevated triglycerides, low levels of protective HDL cholesterol, high fasting blood sugar and raised blood pressure. When at least three of these appear together, the risk of type 2 diabetes and cardiovascular disease climbs sharply. Globally, an estimated 12.5 to 31.4 percent of adults live with the condition, and its prevalence is rising, straining health systems and driving morbidity and mortality. What makes the syndrome so insidious is that its root cause, dysfunctional visceral fat wrapped around internal organs, is difficult to see and even harder to measure with a tape measure alone.

That is where VAI enters the picture. Introduced by Amato and colleagues in 2010, the index was originally modelled on 315 healthy nonobese subjects and validated in nearly 1,500 primary care patients. Unlike body mass index or waist circumference, which estimate fat quantity, VAI attempts to gauge fat function. Its formula combines waist circumference and BMI with triglycerides and HDL cholesterol, using different constants for men and women. In the original validation, VAI correlated inversely with insulin sensitivity measured by the gold-standard euglycemic-hyperinsulinemic clamp, while neither waist circumference nor BMI showed any correlation. It also independently predicted cardiovascular and cerebrovascular events, suggesting it was tapping into something the older measures missed.

The new study put the index through one of its most demanding real-world tests yet. Researchers analysed baseline data from 10,520 adults aged 35 to 70 enrolled in the PERSIAN Guilan Cohort in northern Iran. Participants underwent standardized physical examinations, structured interviews and fasting blood tests in a certified central laboratory. Metabolic syndrome was diagnosed using the ATP III criteria, requiring at least three of the five components. The results were striking: 40.7 percent of the cohort met the criteria, but the burden was heavily skewed by sex. Among men, prevalence was 24.5 percent; among women, it reached a remarkable 54.7 percent.

The numbers for VAI itself told a similar story. People with metabolic syndrome had a median VAI of 3.31, compared with 1.64 in those without the condition. In logistic regression models, each one-unit increase in VAI was associated with roughly 2.4-fold higher odds of metabolic syndrome, an association that barely budged after adjustment for age, sex, lipid-lowering medication, urban or rural residence, education, alcohol use and smoking. When participants were sorted into quartiles, the gradient was dramatic: odds ratios of 2.45, 9.42 and 41.35 for the second, third and fourth quartiles respectively, compared with the lowest.

Sex mattered. A formal interaction test confirmed that the association was significantly stronger in women than in men, with each unit of VAI carrying an odds ratio of 3.20 in women versus 1.92 in men. In the highest quartile, women faced 60.5-fold higher odds of metabolic syndrome compared with the lowest quartile, while men in the same position faced 55.2-fold higher odds. The researchers also examined each component of the syndrome separately. The strongest links were with elevated triglycerides and low HDL cholesterol, the two lipid parameters built into the VAI formula, but the index was also significantly associated with high fasting glucose, elevated blood pressure and increased waist circumference, components not directly embedded in the equation.

Diagnostic performance was assessed with receiver operating characteristic analysis. VAI alone achieved an area under the curve of 0.835 in the total population, with similar values in men and women, indicating good discrimination. Optimal cut-off points, derived using Youden’s Index, came out at 2.42 overall, 2.08 for men and 2.69 for women. Perhaps most tellingly, VAI outperformed every comparator tested: the triglyceride-to-HDL cholesterol ratio scored an AUC of 0.775, waist-to-height ratio 0.756, waist circumference 0.737 and body mass index just 0.715. The composite structure of the index, mixing anthropometric and biochemical signals, appears to capture cardiometabolic risk more effectively than any single measure.

The findings align with a widening international literature. A meta-analysis reported a pooled AUC of 0.847 for VAI in detecting metabolic syndrome, and studies in Spanish workers, Saudi cohorts, elderly Chinese adults and young adults have repeatedly shown the index matching or beating conventional measures. VAI has also proven relevant in high-risk groups, including women with polycystic ovary syndrome, patients with chronic kidney disease, people with suspected obstructive sleep apnea and children with obesity, where it often outperformed rivals such as the Lipid Accumulation Product and HOMA-IR. The consistency across ages, ethnicities and clinical settings hints that visceral fat dysfunction is a genuinely universal axis of metabolic disease.

The authors are careful about the caveats. Because the study is cross-sectional, it shows association with prevalent metabolic syndrome, not prospective prediction of future disease. More importantly, there is partial mathematical overlap: VAI incorporates waist circumference, triglycerides and HDL cholesterol, which are also components of the ATP III definition, so the enormous odds ratios in the top quartile should not be read as a purely independent biological effect. The skewed distribution of VAI, with a long upper tail, and the fact that the cut-off values were derived and tested in the same dataset add further caution. External validation in other populations and longitudinal follow-up will be essential before the thresholds can guide screening.

Even with those limitations, the practical appeal is obvious. VAI requires nothing more than a scale, a tape measure and two lipid values that are already ordered in routine check-ups, making it an attractive tool for early risk stratification, particularly in low- and middle-income countries where advanced imaging is scarce. The subgroup analyses showed the association held steady across age, marital status, education, occupation and BMI categories, suggesting robustness in diverse population segments. If future prospective studies confirm its predictive value, this unglamorous formula, multiplying a waist measurement by a ratio of blood fats, could become one of the cheapest and most effective gatekeepers against the coming wave of diabetes and heart disease.

Subject of Research: Association between the Visceral Adiposity Index and metabolic syndrome in the PERSIAN Guilan Cohort

Article Title: Association Between Visceral Adiposity Index and Metabolic Syndrome and Its Components: Evidence From the PERSIAN Guilan Cohort Study

Article References: Letafatkar, N., Amini‐Salehi, E., Hashemi, S. M., Hassanipour, S., Jafari, M., Ghaffari, S., Joukar, F., & Mansour‐Ghanaei, F. (2026). Association Between Visceral Adiposity Index and Metabolic Syndrome and Its Components: Evidence From the PERSIAN Guilan Cohort Study. Endocrinology, Diabetes & Metabolism, 9(5), Article e70341. https://doi.org/10.1002/edm2.70341

Image Credits: AI Generated

DOI: 10.1002/edm2.70341

Keywords: visceral adiposity index, metabolic syndrome, obesity, insulin resistance, triglycerides, HDL cholesterol, cardiometabolic risk, PERSIAN Guilan Cohort, Iran, epidemiology, BMI, screening